#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Charlotte Edenius Email
VP Clinical R&D . Gesynta Pharma AB
Stockholm,
LocationPrimary Email
How to contact Charlotte Edenius
Join and see Charlotte's contact info for free!Current Roles
Employees:
19Revenue:
$3.8MAbout
Gesynta Pharma's drug candidate vipoglanstat (GS-248) is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life, and current drug treatments are inadequate for many patients. \n\nGesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy.\n\nGesynta Pharma’s second drug candidate to reach clinical development, GS-073, has the same mode of action as vipoglanstat. GS-073 is ready to enter clinical phase I for the treatment of chronic inflammatory pain.\n\nGesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.Gesynta Pharma AB Address
Stockholm, null
SWE